1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Benchmarking European Investigator Payments

Benchmarking European Investigator Payments

  • January 2014
  • -
  • Industry Standard Research
  • -
  • 104 pages

This report provides an analysis of Europe’s clinical trial compensation for investigator payments across 18 therapeutic areas, 5 compound types, and the 4 phases of development.  It provides pharmaceutical, biotech, and service providers an opportunity to gain a better understanding of what drives investigator payments so they can benchmark their payment levels and better plan for study costs.

What you will learn in this report:
- Average compensation investigators receive per subject for each therapy area by phase and compound orientation/ type
- How study characteristics (length and complexity) change fee levels
- What motivates investigators to participate in a trial
- Therapeutic area profiles

How you can use this report:
- Optimize your investigator payments across therapeutic areas, phases of development, compound type under investigation, and geography
- Establish and better negotiate investigator payments
- Use “trial complexity” and “length of study” as variables to create more accurate budget projections and lower costs

Valuable for:
- Project Management
- Clinical Operations
- Outsourcing
- Trial Budgeting
- Feasibility
- CRO Proposals

Table Of Contents

Benchmarking European Investigator Payments
Table of Contents

Copyright and Usage Guidelines ..5
Introduction .6
Methodology ...7
Respondent Demographics and Qualifications 8
Primary Role at Research Site 8
Office Location by Geography 8
Office Setting ..8
Major Sections .9
Executive Summary 11
Average Compensation per Patient .12
Average Compensation per Patient by Region 13
Average Compensation across Phases .14
Average Compensation across Compound Orientations .14
Average Compensation per Patient by Therapeutic Area and Phase ..15
Average Compensation per Patient by Therapeutic Area and Compound Orientation...16
Appeal of Innovative Compounds 17
Milestone Payment Plans .17
Payment Negotiation Environment ..17
Benchmarking Investigator Fees 18
Phase Comparison by Specialty/ Therapeutic Areas 19
Phase I ...19
Phase II .20
Phase III .21
Phase IV 22
Compound Orientation Compensation by Specialty/ Therapeutic Area .23
Biologic .23
Biosimilar ..24
Me-too ..25
Generic .26
Novel .27
Region comparison by Phase ...28
Phase I ...28
Phase II ..29
Phase III 30
Phase IV 31
Region Comparison by Compound Orientation ...32
Novel .32
Generic .33
Me-too ..34
Biosimilar ..35
Biologic .36
Investigator Payment Dynamics 37
Most Researched Medical Specialties/ Therapeutic Areas ..38
Number of Studies Managed in the Past 24 Months by Therapeutic Area .39
Therapeutic Areas conducted at sites vs. Number of studies managed in a Therapeutic Area ...40
Views of Trial Site Capacity ..41
Most Frequent Payment Models Used 42
Most Frequent Payment Milestones Used ..43
Payment Milestone Preference ...44
Top Non-monetary Incentives for Site Trial Participation ...45
Geographic Differences for Non-monetary incentives 46
Master Service Agreements (MSA) ..47
Drivers of Investigator Fees ...48
Most Influential Motivators for Site Participation in a Study ..49
Study Characteristics that Warrant Higher Fees ..50
Site Motivation for Clinical Trial Participation .51
Appeal of Innovative New Compound Studies 52
Likelihood to Participate in Complex Clinical Trials .53
How Study Complexity Impacts Higher Fees ...54
Leading Driver for Increased Fee .54
How Study Complexity Impacts Lower Fees 55
Study Complexity Impact Table ...56
How Study Length Impacts Higher Fees ..57
How Study Length Impacts Lower Fees ...58
Study Length Impact Table ..58
Profiled Specialty/ Therapeutic Analysis 59
Analgesic / Pain Management .60
Cardiovascular .62
CNS ...64
Dermatology 66
Gastrointestinal ...68
Hematology ..70
Infectious Diseases ...72
Internal Medicine .74
Metabolic Diseases ..76
Musculoskeletal / Arthritis ..78
Oncology ..80
Ophthalmology 82
Orthopedics .84
Pediatric ...86
Respiratory / Allergy / Pulmonology 88
Urology 90
Vaccines ...92
Women's Health ..94
Site and Respondent Demographics ..96
Management to Determine Site Compensation ..97
Primary Role at Research Site ..97
Years in Clinical Trials ...98
Office Location .99
Office Setting ...99
Medical Specialties/ Therapeutic Areas .100
Negotiated Investigator Fees .101
Clinical Trial Participation ..101
Office Location in Western Europe 102
Location in Eastern Europe 102
Sites Revenue from Clinical Trials ..103
About Industry Standard Research ..104

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.